-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network January 18, January 15, CDE official website shows that Yangzijiang Pharmaceutical Group's hydrochloric acid Praxo slow release tablets to copy 4 categories of applications for listing was accepted.
, stone pharmaceutical group Europic acid Prakso slow release tablets submitted for listing applications were also accepted. according to
meters of intranet data, in 2019 in China's public medical institutions terminal and China's urban physical pharmacy terminal Praxo tablet sales of more than 800 million yuan, of which, the original research drug Bronger Ingham market share of more than 95%.
data show that Plaxo is a new generation of non-amine dopamine-like inhibitor excitants, high bio-utilization, rapid drug efficacy, not affected by food, for combined depression parkinson's patients have a good effect.
the drug was approved by the FDA in 1997 for the treatment of primary Parkinson's disease (PD), Praxo can be used at all stages of PD and can be used alone in early PD, or as an auxiliary therapy in association with lon doppeliotherapy for advanced PD.
, Praxo is a first-line drug recommended by PD guidelines at home and abroad.
source: Milnet one-click search Minet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal and China's urban physical pharmacy terminal Praxo tablets total sales of more than 800 million yuan, of which, the original research drug Bronger Ingham market share of more than 95%.
Hydrochloric acid Praxo slow release tablets production enterprises have Jiangsu Hengrui Pharmaceuticals, Hesco Pharmaceuticals (Meishan), Zhejiang Jingxin Pharmaceuticals 3 domestic enterprises, are in the second half of 2020 to copy 4 categories approved, and as reviewed.
This year, Yangzijiang Pharmaceutical Group and Shi Pharmaceutical Group Oyepel Pharmaceuticals submitted their applications for listing in the review and approval (in the drug review center), before, Chengdu Baiyu Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group, Chengdu Bett Pharmaceuticals, Qilu Pharmaceuticals (Hainan) and other enterprises have submitted applications for listing in the review and approval (in the drug review center).
source: MED2.0 China Drug Review Database Source: CDE official website, Minet database